(Q38496627)

3 September 2017

1 reference

title

CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants (English)

1 reference

3 September 2017

1

Vincent Haufroid

1 reference

3 September 2017

Philippe Hantson

2

1 reference

3 September 2017

language of work or name

English

0 references

publication date

22 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

53

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

501-510

1 reference

Molecular basis of polymorphic drug metabolism

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Polymorphisms in CYP2D6 may predict methamphetamine related heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Investigation of morphine and morphine glucuronide levels and cytochrome P450 isoenzyme 2D6 genotype in codeine-related deaths.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Fatal and severe codeine intoxication in 3-year-old twins--interpretation of drug and metabolite concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Suspected opioid overdose case resolved by CYP2D6 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Death of a 10-month-old boy after exposure to ethylmorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

A fatal doxepin poisoning associated with a defective CYP2D6 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Time course of clinical response to venlafaxine: relevance of plasma level and chirality

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Alternative venlafaxine kinetics in overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563650.2015.1049355

10.3109/15563650.2015.1049355

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference